22 September 2020 : Clinical Research
Urachal Carcinoma: Are Lymphadenectomy and Umbilectomy Necessary?
Zhuo Jia1ABCDEF*, Xiao Chang1ABCD, Xing Li1BC, Baojun Wang1AE, Xu Zhang1AFDOI: 10.12659/MSM.927913
Med Sci Monit 2020; 26:e927913
Table 5 Chemotherapy and radiographic response.
| Regimen | CR/PR | SD | PD | Total |
|---|---|---|---|---|
| Cisplatin-based | 4 (30.8%) | 5 (38.4%) | 4 (30.8%) | 13 |
| Cisplatin+gemcitabine | 2 (40%) | 1 (20%) | 2 (40%) | 5 |
| Cisplatin+paclitaxel | 1 (20%) | 2 (40%) | 2 (40%) | 5 |
| Cisplatin+5-FU | 1 (100%) | 0 | 0 | 1 |
| Cisplatin+PD-1 inhibitor | 0 | 2 (100%) | 0 | 2 |
| Others | 0 | 2 (66.7%) | 1 (33.3%) | 3 |
| CR – complete response; PR – partial response; SD – stable disease; PD – progressive disease. | ||||